Hologic, Inc. (HOLX)

Over the past six months, Hologic's stock price has increased. Recent financial results have impacted the stock, with Q4 FY2025 and Q1 FY2026 missing revenue and EPS estimates, leading to analyst downgrades. There has been news regarding a potential buyout of Hologic by Blackstone and TPG, with the Hologic board recommending shareholders vote in favor of this sale. Institutional activity has shown a mixed trend.

While specific seasonal patterns are not explicitly outlined, factors can introduce variability in demand. Hologic plans conservatively for the respiratory season and has faced headwinds from external factors like a shortage of saline IV fluids. Certain product lines or market conditions can experience seasonality or temporary fluctuations.

Hologic, Inc. is a global medical technology company focused on women's health, specializing in diagnostics, medical imaging, and surgical products. The company operates in the Healthcare sector, specifically in the Medical Instruments & Supplies and Diagnostic Equipment industries. Its business is divided into four segments: Diagnostics, which includes molecular diagnostic systems; Breast Health, offering solutions for breast cancer care; GYN Surgical, including endometrial ablation devices; and Skeletal Health, providing bone imaging systems.

Hologic, Inc. is headquartered in Marlborough, Massachusetts, U.S., and has a global presence with locations in over 36 countries and more than 7,000 employees. The United States is the largest revenue contributor, followed by Europe, Asia, and other international markets.

Hologic has received positive recognition as an employer, including being listed among Forbes' "America's Best Midsize Employers" and "World's Best Employers." These accolades suggest a strong reputation as a workplace.

Hologic, Inc. has a significant institutional ownership base. Major institutional owners include The Vanguard Group, Inc., BlackRock, Inc., and State Street Corp. Carl C. Icahn has been noted as a significant individual shareholder in the past.